Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan - Scorecard - MDSpire

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan

  • By

  • Hideyo Kasai

  • Taro Yasumoto

  • Shota Kosuge

  • Ayako Osanai

  • Keita Mizuma

  • Akinori Futamura

  • Takeshi Kuroda

  • Kenjiro Ono

  • Hidetomo Murakami

  • May 13, 2026

  • 0 min

Share

Clinical Scorecard: Long-term Real-World Outcomes and Treatment Adherence of Anti-CGRP Monoclonal Antibodies for Migraine Prevention: A Three-Year Single-Center Study from Japan

At a Glance

CategoryDetail
ConditionMigraine
Key MechanismsTargeting calcitonin gene-related peptide (CGRP) involved in migraine pathophysiology.
Target PopulationIndividuals aged ≥15 years with episodic migraine, high-frequency episodic migraine, or chronic migraine.
Care SettingTertiary neurology/headache clinic.

Key Highlights

  • 56% of subjects maintained treatment for 3 years.
  • Monthly migraine days reduced from 12.0 to 5.6 at 36 months.
  • Responder rates at 36 months: ≥50% (55.6%), ≥75% (29.6%), 100% (11.1%).
  • Cessation of treatment often due to achievement of treatment objectives (24%).
  • No discontinuations due to adverse events.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on International Classification of Headache Disorders, 3rd edition (ICHD-3).

Management

  • Use of galcanezumab or fremanezumab for migraine prevention.

Monitoring & Follow-up

  • Assess monthly migraine days, MIDAS, HIT-6, and VAS at baseline and at 1, 3, 6, 12, and 36 months.

Risks

  • No adverse events reported leading to discontinuation.

Patient & Prescribing Data

50 subjects aged ≥15 years with migraine.

Long-term efficacy and tolerability of anti-CGRP monoclonal antibodies in standard clinical settings.

Clinical Best Practices

  • Facilitate collaborative decision-making on treatment maintenance or discontinuation.
  • Tailor dosing approaches based on individual patient needs.

Related Resources & Content

Original Source(s)

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan

  • by Hideyo Kasai, Taro Yasumoto, Shota Kosuge, Ayako Osanai, Keita Mizuma, Akinori Futamura, Takeshi Kuroda, Kenjiro Ono, Hidetomo Murakami

  • May 13, 2026

Related Content

Atherogenic index of plasma and severe headaches or migraines risk in US adults: a population-based cross-sectional analysis from NHANES 1999–2004

Model May Reframe Tension-Type Headache

Proposed framework organizes interacting factors into four domains to guide personalized assessment

Cognitive Impairment Associated with Mild to Moderate Migraine Episodes: Possible Effects on Workplace Attendance